Risks of non-prescription medication as shown by clobutinol as an example;Risiken nicht verschreibungspflichtiger medikamente: Aktuelles beispiel silomat® hustensaft

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 4, 2008, Pages 144-146

  Rottlaender, D ^a   Hoppe, Uta C ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Clobutinol; Non prescription drugs; QT interval prolongation; Serious adverse effect

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIRHEUMATIC AGENT; CLOBUTINOL; AMINOALCOHOL; ANTITUSSIVE AGENT; NON PRESCRIPTION DRUG;

HEART DEPOLARIZATION; HOSPITALIZATION; HUMAN; NOTE; PRESCRIPTION; QT DISPERSION; RISK ASSESSMENT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHILD; COUGHING; DRUG CONTRAINDICATION; DRUG INTERACTION; LONG QT SYNDROME; MALE; SYNCOPE; TACHYCARDIA; TORSADE DES POINTES;

AMINO ALCOHOLS; ANTITUSSIVE AGENTS; CHILD; COUGH; DRUG INTERACTIONS; DRUGS, NON-PRESCRIPTION; HUMANS; LONG QT SYNDROME; MALE; SYNCOPE; TACHYCARDIA; TORSADES DE POINTES;

EID: 38149022673     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1017490     Document Type: Note

References (5)

1. Bellocq C, Wilders R, Schott JJ et al. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol 2004; 66: 1093-1102
2. Boehringer-Ingelheim-GmbH. Expert Statement on the non-clinical and clinical evaluation of the potential for delayed ventricular repolarization (QT Interval prologation) by Clobutinol. www.bfarm.de2007
3. Bundesvereinigung-Deutscher-Apothekenverbände. Die Apotheke - Zahlen, Daten, Fakten. www.abda.de2006
4. Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA 1974; 228: 713-717
5. Rottlaender D, Scherner M, Schneider T, Erdmann E. Multimedikation, Compliance und Zusatzmedikation bei Patienten mit kardiovaskulären Erkrankungen. Dtsch Med Wochenschr 2007; 132: 139-144